The workshop New Paradigms in Drug Discovery: How Genomic Data Are Being Used to Revolutionize the Drug Discovery and Development Process had three broad objectives:
1. To examine the impact of and investment in genetic and genomic technologies and data in drug discovery and development.
2. To examine and discuss the challenges for incorporating genomic technologies into drug development and to explore solutions to remedy those challenges.
3. To discuss and explore how innovative, novel, and global partnerships between academia, industry, foundations, and government can enable the use of genomic information for more efficient and effective drug discovery and development programs.
ing of the mechanisms of disease as well as individual patients’ reactions to their medications. Warfarin, Gleevec®, XALKORI®, Kalydeco™, and Zelboraf® are all examples of pharmaceuticals that utilize genetic information to inform dosing or whose activity and effectiveness is determined by inherent genetic properties of the patient or their tumor (i.e., a targeted therapeutic). However, even with these successes there remains skepticism over how useful genomic information will be to the larger drug development process (Pollack, 2010; Wade, 2010). There is a need to identify the success factors for the various models that are being developed, whether they are industry-led, academia-led, or collaborations between the two.
The Roundtable on Translating Genomic-Based Research for Health held a workshop on March 21, 2012, titled New Paradigms in Drug Discovery: How Genomic Data Are Being Used to Revolutionize the Drug Discovery and Development Process. The purpose of the workshop was to examine the general approaches being used to apply genomic-based research results to the discovery and development of new drugs, the successes achieved so far, and the challenges ahead.2
2 The full statement of task can be found in Appendix C.